S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:HLVX

HilleVax (HLVX) Stock Forecast, Price & News

$17.94
-0.56 (-3.03%)
(As of 05:40 PM ET)
Compare
Today's Range
$17.32
▼
$18.61
50-Day Range
$12.93
▼
$18.76
52-Week Range
$7.90
▼
$24.42
Volume
76,005 shs
Average Volume
57,042 shs
Market Capitalization
$703.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

HilleVax MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
5.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of HilleVax in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.55) to ($3.12) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.76 out of 5 stars

See Top Rated MarketRank™ Stocks Here

HLVX stock logo

About HilleVax (NASDAQ:HLVX) Stock

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Receive HLVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter.

HLVX Stock News Headlines

June 7, 2023 | finance.yahoo.com
Wall Street Analysts Predict a 56.76% Upside in HilleVax, Inc. (HLVX): Here's What You Should Know
June 7, 2023 | finance.yahoo.com
Wall Street Analysts Predict a 56.76% Upside in HilleVax, Inc. (HLVX): Here's What You Should Know
June 7, 2023 | MarketBeat Internal (Ad)
Save $200 on MarketBeat All Access
MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $200 account credit and free 30-day trial subscription today.
May 30, 2023 | markets.businessinsider.com
Stifel Nicolaus Sticks to Its Buy Rating for HilleVax, Inc (HLVX)
May 25, 2023 | markets.businessinsider.com
Stifel Nicolaus Reaffirms Their Buy Rating on HilleVax, Inc (HLVX)
May 22, 2023 | finance.yahoo.com
How Much Upside is Left in HilleVax, Inc. (HLVX)? Wall Street Analysts Think 87.76%
May 19, 2023 | americanbankingnews.com
HilleVax (NASDAQ:HLVX) Sees Strong Trading Volume
May 16, 2023 | msn.com
JP Morgan Maintains HilleVax (HLVX) Overweight Recommendation
June 7, 2023 | MarketBeat Internal (Ad)
Save $200 on MarketBeat All Access
MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $200 account credit and free 30-day trial subscription today.
May 16, 2023 | markets.businessinsider.com
J.P. Morgan Keeps Their Buy Rating on HilleVax, Inc (HLVX)
May 13, 2023 | finanznachrichten.de
HilleVax, Inc.: HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 12, 2023 | msn.com
HilleVax: Q1 Earnings Insights
May 12, 2023 | finance.yahoo.com
HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 9, 2023 | finance.yahoo.com
HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors
May 5, 2023 | americanbankingnews.com
HilleVax (HLVX) & Its Competitors Financial Survey
May 4, 2023 | americanbankingnews.com
HilleVax (HLVX) & Its Peers Financial Comparison
April 26, 2023 | americanbankingnews.com
HilleVax (HLVX) and Its Peers Financial Contrast
April 26, 2023 | americanbankingnews.com
Comparing HilleVax (HLVX) and Its Competitors
April 25, 2023 | finance.yahoo.com
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
April 8, 2023 | americanbankingnews.com
HilleVax (HLVX) & Its Peers Head-To-Head Analysis
April 8, 2023 | americanbankingnews.com
HilleVax (HLVX) vs. Its Peers Financial Analysis
March 31, 2023 | americanbankingnews.com
HilleVax (NASDAQ:HLVX) Stock Price Up 8.8%
March 25, 2023 | americanbankingnews.com
Q1 2023 Earnings Estimate for HilleVax, Inc. (NASDAQ:HLVX) Issued By SVB Leerink
March 22, 2023 | americanbankingnews.com
HilleVax, Inc. (NASDAQ:HLVX) to Post Q1 2024 Earnings of ($0.91) Per Share, SVB Leerink Forecasts
March 20, 2023 | finanznachrichten.de
HilleVax, Inc.: HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
March 17, 2023 | finance.yahoo.com
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
January 9, 2023 | finance.yahoo.com
HilleVax Announces Executive Management Appointments and Promotions
See More Headlines

HLVX Price History

HLVX Company Calendar

Last Earnings
5/12/2023
Today
6/07/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HLVX
CUSIP
N/A
CIK
1888012
Web
www.hillevax.com
Phone
617-213-5054
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.75)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-159,810,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-43.18%
Return on Assets
-37.09%

Debt

Debt-to-Equity Ratio
0.06
Current Ratio
14.00
Quick Ratio
14.00

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.01 per share
Price / Book
2.24

Miscellaneous

Outstanding Shares
39,200,000
Free Float
27,714,000
Market Cap
$702.86 million
Optionable
Not Optionable
Beta
0.04

Key Executives

  • Dr. Robert M. Hershberg M.D.Dr. Robert M. Hershberg M.D. (Age 61)
    Ph.D., Pres, CEO & Chairman
    Comp: $611.2k
  • Mr. David A. SocksMr. David A. Socks (Age 48)
    CFO & Chief Bus. Officer
    Comp: $561.72k
  • Mr. Aditya Kohli Ph.D. (Age 35)
    COO & Director
    Comp: $576.55k
  • Dr. Anju Chatterji Ph.D.
    Sr. VP of Technical Operations
  • Mr. Paul S. Bavier J.D. (Age 51)
    Gen. Counsel, Sec. & Chief Admin. Officer
  • Ms. Astrid Borkowski M.D. (Age 53)
    Ph.D., Chief Medical Officer
  • Ms. Kaia Agarwal
    Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













HLVX Stock - Frequently Asked Questions

How have HLVX shares performed in 2023?

HilleVax's stock was trading at $16.73 on January 1st, 2023. Since then, HLVX stock has increased by 7.2% and is now trading at $17.93.
View the best growth stocks for 2023 here.

When is HilleVax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our HLVX earnings forecast.

How were HilleVax's earnings last quarter?

HilleVax, Inc. (NASDAQ:HLVX) released its quarterly earnings results on Friday, May, 12th. The company reported ($0.71) earnings per share for the quarter, beating analysts' consensus estimates of ($0.96) by $0.25.

What ETFs hold HilleVax's stock?

ETFs with the largest weight of HilleVax (NASDAQ:HLVX) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB),

When did HilleVax IPO?

(HLVX) raised $200 million in an initial public offering on Friday, April 29th 2022. The company issued 11,765,000 shares at $16.00-$18.00 per share.

What is HilleVax's stock symbol?

HilleVax trades on the NASDAQ under the ticker symbol "HLVX."

Who are HilleVax's major shareholders?

HilleVax's stock is owned by many different institutional and retail investors. Top institutional investors include Carlyle Group Inc. (4.69%), Franklin Resources Inc. (3.28%), BlackRock Inc. (2.65%), Geode Capital Management LLC (0.73%), State Street Corp (0.70%) and Fred Alger Management LLC (0.22%).

How do I buy shares of HilleVax?

Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HilleVax's stock price today?

One share of HLVX stock can currently be purchased for approximately $17.93.

How much money does HilleVax make?

HilleVax (NASDAQ:HLVX) has a market capitalization of $702.86 million. The company earns $-159,810,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis.

How can I contact HilleVax?

The official website for the company is www.hillevax.com. The company can be reached via phone at 617-213-5054 or via email at ir@hillevax.com.

This page (NASDAQ:HLVX) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -